This proposal seeks to continue a Clinical Hematology Career Development Program in benign hematology and transfusion medicine at the Johns Hopkins Medical Institutions (JHMI). The next generation of clinical researchers in benign hematology and transfusion medicine will need to include individuals with the skills, attitudes, early research training and experience to capitalize on rapidly developing progress in these disciplines. In developing this program, we will use established research infrastructure, including free-standing Divisions of Hematology in Pediatrics, Internal Medicine and Transfusion Medicine that are dedicated to the care and study of benign hematologic disorders, as well as our Graduate Training Program in Clinical Investigation (GTPCI) at the Johns Hopkins University School of Medicine and Johns Hopkins University Bloomberg School of Public Health.
Our specific aims are: a) To continue to identify, recruit, train and develop creative and successful clinical investigators, with the capability to interact with, participate in, and lead multidisciplinary teams involved in clinical research, address complex problems and become national leaders in pediatric, adolescent and adult benign hematology and transfusion medicine;b) To provide trainees with the requisite skills, knowledge, attitude and experience for successful academic careers in clinical research in these areas. This training will include exposure to national and international leaders and curriculum in the multiple disciplines necessary for successful clinical research, including benign hematology, transfusion medicine, clinical trials design, epidemiology, statistics, research ethics and human subjects protection;c) To provide a rich mentoring environment. We will integrate multiple research resources and investigators available at the JHMI to provide optimal exposure of trainees to research experiences and training. We will continue to focus our efforts in six areas where we feel there is particular strength within our institution: bone marrow failure and stem cell biology, sickle cel disease (SCD), myeloproliferative disorders, transfusion medicine, outcomes research and genetics. We will work with several established investigators and mentors to develop a structured curriculum in benign hematology and strong mentored research experiences for trainees. Careful and extensive mentoring will be the cornerstone of these efforts, with exposure to cutting edge research experiences. Through this program, we ultimately aim to provide a cadre of clinical researchers, who will become creative, independent investigators, care for patients and assume leadership roles in benign clinical hematology.

Public Health Relevance

Many diseases of the blood (hematologic) are serious, but rare, and need to be better studied and treated. Most physicians specializing in hematology train in both oncology (cancer) and hematology;as reimbursement for the treatment of cancer is better than for hematologic conditions, the number of hematologists (blood doctors) and transfusion medicine specialists seems to be decreasing. This project aims to assure that there will be enough well trained hematologists in the future with the skills and knowledge necessary to address complex problems in blood diseases and transfusion medicine and care for the patients with these disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12HL087169-07
Application #
8464193
Study Section
Special Emphasis Panel (ZHL1-CSR-J (F1))
Program Officer
Mondoro, Traci
Project Start
2006-09-01
Project End
2017-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
7
Fiscal Year
2013
Total Cost
$323,776
Indirect Cost
$23,983
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Naik, Rakhi P; Wilson, James G; Ekunwe, Lynette et al. (2016) Elevated D-dimer levels in African Americans with sickle cell trait. Blood 127:2261-3
Li, Ruijuan; Sobreira, Nara; Witmer, P Dane et al. (2016) Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. Haematologica 101:e228-31
Yu, Tiffany T; Nelson, Julie; Streiff, Michael B et al. (2016) Risk factors for venous thromboembolism in adults with hemoglobin SC or Sβ(+) thalassemia genotypes. Thromb Res 141:35-8
Razdan, Sheila; Strouse, John J; Reddy, Anusha et al. (2016) Patent foramen ovale in adults with sickle cell disease and stroke. Am J Hematol 91:E358-60
Braunstein, E M; Li, R; Sobreira, N et al. (2016) A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia. Leukemia 30:2242-2245
Churpek, Jane E; Pyrtel, Khateriaa; Kanchi, Krishna-Latha et al. (2015) Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 126:2484-90
Lance, Eboni I; Comi, Anne M; Johnston, Michael V et al. (2015) Risk Factors for Attention and Behavioral Issues in Pediatric Sickle Cell Disease. Clin Pediatr (Phila) 54:1087-93
Brousseau, David C; Scott, J Paul; Badaki-Makun, Oluwakemi et al. (2015) A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 126:1651-7
Smith, Cory; Abalde-Atristain, Leire; He, Chaoxia et al. (2015) Efficient and allele-specific genome editing of disease loci in human iPSCs. Mol Ther 23:570-7
Folsom, A R; Tang, W; Roetker, N S et al. (2015) Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost 13:2-9

Showing the most recent 10 out of 46 publications